Sideroflexin1 As a Novel Tumor Marker Independently Predicts Survival in Lung Adenocarcinoma

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35116859

Authors

Qijiu Chen

Rong Wang

Jianyong Zhang

Liang Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Targeted therapy for lung cancers is based on prognostic genes and needs more investigation. No study has yet evaluated the effects of Sideroflexin1 (SFXN1) on lung cancer.

Methods: Data were analyzed from large patient cohorts in the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO).

Results: The mRNA and protein expression of SFXN1 is apparently upregulated in lung adenocarcinoma (LUAD) tissues. Among LUAD patients, upregulated SFXN1 mRNA expression can independently predict unfavorable overall survival (OS, P=0.006) and recurrence-free survival (RFS; P=0.003). In addition, detection data from DNA copy number alterations (CNAs) showed that 164 (32.03%) of the 512 cases had copy number loss (-2 and -1), while 121 (23.63%) of the cases had copy number amplification (+1 and +2). We also found a weak negative correlation between the methylation status of one CpG site (chr5: 174, 944, 791-174, 944, 793) and SFXN1 expression (P<0.0001).

Conclusions: Upregulated SFXN1 mRNA expression can be a prognostic biomarker of unfavorable OS and RFS in patients with LUAD.

Citing Articles

Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers.

Huang H, Lian H, Liu W, Li B, Zhu R, Shao H Hum Genomics. 2025; 19(1):10.

PMID: 39915876 PMC: 11803981. DOI: 10.1186/s40246-024-00705-6.

Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.

Liu W, Du Q, Mei T, Wang J, Huang D, Qin T BMC Cancer. 2024; 24(1):94.

PMID: 38233752 PMC: 10795352. DOI: 10.1186/s12885-023-11646-z.

References

Huang H, Zheng J, Shen N, Wang G, Zhou G, Fang Y . Identification of pathways and genes associated with synovitis in osteoarthritis using bioinformatics analyses. Sci Rep. 2018; 8(1):10050. PMC: 6030156. DOI: 10.1038/s41598-018-28280-6. View

Rudin S, Marable M, Huang R . The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics. 2017; 15(2):82-93. PMC: 5414888. DOI: 10.1016/j.gpb.2016.11.003. View

Hildick-Smith G, Cooney J, Garone C, Kremer L, Haack T, Thon J . Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. Am J Hum Genet. 2013; 93(5):906-14. PMC: 3824126. DOI: 10.1016/j.ajhg.2013.09.011. View

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

Torre L, Siegel R, Jemal A . Lung Cancer Statistics. Adv Exp Med Biol. 2015; 893:1-19. DOI: 10.1007/978-3-319-24223-1_1. View

Loo J, Scherl A, Nguyen A, Man F, Weinberg E, Zeng Z . Extracellular metabolic energetics can promote cancer progression. Cell. 2015; 160(3):393-406. PMC: 4312495. DOI: 10.1016/j.cell.2014.12.018. View

Amorim I, Graham L, Carter R, Morton N, Hammachi F, Kunath T . Sideroflexin 3 is an α-synuclein-dependent mitochondrial protein that regulates synaptic morphology. J Cell Sci. 2017; 130(2):325-331. PMC: 5278670. DOI: 10.1242/jcs.194241. View

Cheung A, Opzoomer J, Ilieva K, Gazinska P, Hoffmann R, Mirza H . Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clin Cancer Res. 2018; 24(20):5098-5111. PMC: 6193548. DOI: 10.1158/1078-0432.CCR-18-0652. View

Newman A, Maddocks O . One-carbon metabolism in cancer. Br J Cancer. 2017; 116(12):1499-1504. PMC: 5518849. DOI: 10.1038/bjc.2017.118. View

10.

Hsu C, Tseng L, Lee H . Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016; 241(12):1281-95. PMC: 4950268. DOI: 10.1177/1535370216641787. View

11.

Weston C, Klobusicky J, Weston J, Connor J, Toms S, Marko N . Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas. PLoS One. 2016; 11(11):e0166593. PMC: 5127508. DOI: 10.1371/journal.pone.0166593. View

12.

Lan X, Field M, Stover P . Cell cycle regulation of folate-mediated one-carbon metabolism. Wiley Interdiscip Rev Syst Biol Med. 2018; 10(6):e1426. PMC: 11875019. DOI: 10.1002/wsbm.1426. View

13.

Zong W, Rabinowitz J, White E . Mitochondria and Cancer. Mol Cell. 2016; 61(5):667-676. PMC: 4779192. DOI: 10.1016/j.molcel.2016.02.011. View

14.

Konno M, Asai A, Kawamoto K, Nishida N, Satoh T, Doki Y . The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review). Int J Oncol. 2017; 50(4):1057-1063. DOI: 10.3892/ijo.2017.3885. View

15.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

16.

Marengo B, Nitti M, Furfaro A, Colla R, Ciucis C, Marinari U . Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy. Oxid Med Cell Longev. 2016; 2016:6235641. PMC: 4932173. DOI: 10.1155/2016/6235641. View

17.

Singh A, Pandey P, Tewari M, Pandey H, Shukla H . Human mitochondrial genome flaws and risk of cancer. Mitochondrial DNA. 2014; 25(5):329-34. DOI: 10.3109/19401736.2013.796520. View

18.

Scagliotti G, Kortsik C, Dark G, Price A, Manegold C, Rosell R . Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005; 11(2 Pt 1):690-6. View

19.

Lockhart P, Holtom B, Lincoln S, Hussey J, Zimprich A, Gasser T . The human sideroflexin 5 (SFXN5) gene: sequence, expression analysis and exclusion as a candidate for PARK3. Gene. 2002; 285(1-2):229-37. DOI: 10.1016/s0378-1119(02)00402-x. View

20.

Murase R, Abe Y, Takeuchi T, Nabeta M, Imai Y, Kamei Y . Serum autoantibody to sideroflexin 3 as a novel tumor marker for oral squamous cell carcinoma. Proteomics Clin Appl. 2010; 2(4):517-27. DOI: 10.1002/prca.200780123. View